Evidence map›Paper›PMID 38594587›Full record

ArticleNature cell biology2024

CD32 captures committed haemogenic endothelial cells during human embryonic development.

Rebecca Scarfò, Lauren N Randolph, Monah Abou Alezz, Mahassen El Khoury, Amélie Gersch, Zhong-Yin Li, Stephanie A Luff, Andrea Tavosanis, Giulia Ferrari Ramondo, Sara Valsoni and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Nature cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. FcγRIIB functions as an IgG transporter in the mammary gland.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Frontiers in immunology · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 3 countries.

Rebecca Scarfò *San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Lauren N Randolph *San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Monah Abou AlezzSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Mahassen El KhouryUniversité de Strasbourg, Inserm, IRFAC/UMR-S1113, FHU ARRIMAGE, FMTS, Strasbourg, France.
Amélie GerschUniversité de Strasbourg, Inserm, IRFAC/UMR-S1113, FHU ARRIMAGE, FMTS, Strasbourg, France.
Zhong-Yin LiBlack Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stephanie A LuffBlack Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-4259-3839
Andrea TavosanisSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giulia Ferrari RamondoSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Sara ValsoniSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0002-0512-1376
Sara CascioneSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Emma DidelonSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Laura PasseriniSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Giada AmodioSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Chiara BrandasSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0003-1548-6720
Anna VillaSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Silvia GregoriSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ivan MerelliSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Jean-Noël FreundUniversité de Strasbourg, Inserm, IRFAC/UMR-S1113, FHU ARRIMAGE, FMTS, Strasbourg, France.
Christopher M SturgeonBlack Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1508-4414
Manuela TavianUniversité de Strasbourg, Inserm, IRFAC/UMR-S1113, FHU ARRIMAGE, FMTS, Strasbourg, France. manuela.tavian@inserm.fr.ORCID 0000-0003-4746-3240
Andrea DitadiSan Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. ditadi.andrea@hsr.it.ORCID 0000-0003-3283-8943
The San Raffaele Telethon Institute for Gene Therapy · ITInserm · FRIcahn School of Medicine at Mount Sinai · USInstitute of Genetic and Biomedical Research · IT

Funding

Embryonic natural killer cell development and functionR01HL151777 · NHLBI · WASHINGTON UNIVERSITY · PI PALIS, JAMES, STURGEON, CHRISTOPHER MICHAEL · 2020 to 2023
$2.3M
Mesodermal Commitment of the Definitive Hematopoietic ProgramR01HL145290 · NHLBI · WASHINGTON UNIVERSITY · PI STURGEON, CHRISTOPHER MICHAEL · 2019 to 2023
$2.1M
Agence Nationale de la Recherche (French National Research Agency) ANR-14-CE11-0008Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 26779-2021EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101044032Fondazione Telethon (Telethon Foundation) TGT16C04Fondazione Telethon (Telethon Foundation) TGT16G03BFondazione Telethon (Telethon Foundation) TTADC0422TTNHLBI NIH HHS R01 HL145290NHLBI NIH HHS R01 HL151777U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL151777
6 · The paper itself

Abstract

During embryonic development, blood cells emerge from specialized endothelial cells, named haemogenic endothelial cells (HECs). As HECs are rare and only transiently found in early developing embryos, it remains difficult to distinguish them from endothelial cells. Here we performed transcriptomic analysis of 28- to 32-day human embryos and observed that the expression of Fc receptor CD32 (FCGR2B) is highly enriched in the endothelial cell population that contains HECs. Functional analyses using human embryonic and human pluripotent stem cell-derived endothelial cells revealed that robust multilineage haematopoietic potential is harboured within CD32

Indexed as

Embryonic DevelopmentHematopoiesisReceptors, IgGCell DifferentiationCell LineageCells, CulturedEmbryo, MammalianEndothelial CellsGene Expression ProfilingGene Expression Regulation, DevelopmentalHemangioblastsHuman Embryonic Stem CellsHumansPluripotent Stem CellsTranscriptomeReceptors, IgG

Identifiers

PMID38594587
PMCPMC11098737
OpenAlexW4394609516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.